OR WAIT null SECS
June 01, 2022
GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.
May 31, 2022
Through the Thermo Fisher Scientific and LabShares Newton partnership, life science startups can accelerate early-stage discovery and development with shared lab spaces.
May 26, 2022
Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.
May 24, 2022
AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.
Sferalp will use Fluid Air’s PolarDry technology for powder processing.
May 23, 2022
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.
May 16, 2022
Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.
May 13, 2022
Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.
April 27, 2022
GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.
April 22, 2022
Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.